Drug intelligence / Profile preview

Farolax

Development stage: Unknown
Lead developer: Faromed
Modality: Small Molecules
Administration: Oral

Overview

**Farolax** is an oral bowel-cleansing fixed-dose laxative preparation from Faromed for clearance of the bowel before radiography, endoscopy, surgery, and colonoscopy in adults. Each two-sachet pack contains sodium picosulfate 10 mg, magnesium oxide 3.5 g, and citric acid 12 g. Sodium picosulfate acts as a stimulant laxative after colonic activation, while magnesium oxide and citric acid generate an osmotic magnesium citrate solution that retains water in the intestinal lumen and promotes evacuation. ([faromed.at](https://faromed.at/farolax.php))

Brand names: Farolax
Other names: Faro-Lax

Beyond the preview

Go deeper on Farolax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farolax.

Explore the full profile